Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals.

The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therapy for this aggressive ...

May 15, 2025 — A new study suggests that gabapentin, a relatively common anti-seizure/pain medication, is linked to improved survival in patients with glioblastoma (GBM) -- the most common and ...